$MBX News

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism

JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate

Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately

How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide - Slideshow

MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism

MBX Biosciences: In Danger Of Being Outpaced By Rivals - Rating Downgrade

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City